Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI
Overview
Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option. Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.
Full Title of Study: “Evaluation of the Tolerance of Anti-MRSA Betalactamines (Ceftaroline / Ceftobiprole) in the Management of BJI / PJI: a Retrospective Study in a Reference Center”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: May 5, 2020
Interventions
- Other: Description of use of ceftaroline and ceftobiprole
- Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
Arms, Groups and Cohorts
- Description of use of ceftaroline and ceftobiprole
- description of patients and their PJI/BJI,conditions of use, adverse event
Clinical Trial Outcome Measures
Primary Measures
- Evaluation of use of ceftaroline and ceftobiprole : patients
- Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- type of patients: age, CMI
- Evaluation of use of ceftaroline: dosage
- Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- dosage,duration
- Evaluation of use of ceftaroline : PJI/BJI
- Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- description of the PJI/BJI treated by ceftaroline : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection
- Evaluation of use of ceftobiprole: dosage
- Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- dosage, duration
- Evaluation of use of ceftobiprole: PJI/BJI
- Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- description of the PJI/BJI treated by ceftobiprole : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection
- rate of failure under ceftaroline
- Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
- rate of failure under ceftobiprole
- Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
Secondary Measures
- Treatment-related adverse events
- Time Frame: 2 months
- description of adverse event under ceftaroline and/or ceftobiprole as assessed by CTCAE v4.0
Participating in This Clinical Trial
Inclusion Criteria
- patients having had a PJI or BJI treated whith ceftaroline and/or ceftobiprole Exclusion Criteria:
-
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Investigator Details
- Lead Sponsor
- Hospices Civils de Lyon
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.